Brief: Newbury Pharmaceuticals Q3 EBITDA Loss Widens To SEK 3.9 Mln

Newbury Pharmaceuticals AB

14/06/2023 07:11

June 14 (Reuters) - Newbury Pharmaceuticals AB
 NEWBRY.ST :
    * NEWBURY PHARMACEUTICALS INTERIM REPORT SEPTEMBER 2022 –
MAY 2023
    * Q3 NET REVENUE WAS 5 680 (644) TKR
    * Q3 EBITDA WAS -3 872 (-3 100) TKR
    * VALUE OF NEAR-TERM LAUNCH OPPORTUNITIES WILL HELP NEWBURY
INCREASE ITS PROFITABILITY AND SOON REACH AN INFLECTION POINT TO
TURN EBITDA PROFITABLE IN LINE WITH INCREASED SALES ACTIVITIES

Source text for Eikon:  ID:nMFN7x692r 
Further company coverage:  NEWBRY.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))